This is a prospective, open-label, parallel group study to evaluate the efficacy of rosuvastatin 10mg/d or 20mg/d on critical coronary atherosclerosis in Chinese ACS patients. The anticipated duration of the study is approximately 36 weeks, Patients with angiographic luminal diameter narrowing in any non-culprit site between 40%-70% will be enrolled from the study site. The primary efficacy parameter is the percent change of Total Atheroma Volume (TAV) of critical coronary atherosclerosis after 36 weeks of treatment.~For inclusion in the study subjects should fulfill the following criteria:~Provision of informed consent prior to any study specific procedures~18 to 75 years old ACS patients, male or female~The angiographic luminal diameter narrowing in any non-culprit site is between 40%-70%~statin-naive, defined as receiving no statin therapy within 3 monthsThe primary efficacy variable of the study is percent change of TAV from baseline after rosuvastatin 10mg/d or 20mg/d for 36 weeks as determined by IVUS imaging.~The secondary efficacy variables are:~Change of blood lipid level from baseline at 12th, 24th, 36nd week~Change of inflammatory markers from baseline at 36nd week~Change of Percent Atheroma Volume (PAV) as determined by IVUS imaging at 36nd week
The purpose of this study is to determine whether Rosuvastatin 10mg/d or 20mg/d for 36 weeks can regress critical coronary atherosclerosis as determined by IVUS imaging in Chinese Acute Coronary Syndrome (ACS) patients.